NL-OMON38963已完成不适用
Follow-up after treatment of Neisseria gonorrhoeae infections, when and how is a test-of-cure to be included in routine? A prospective observational cohort study - Test-of-cure for Neisseria gonorrhoeae
GGD Amsterdam0 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •18 years or older
- •Infection with Neisseria gonorrhoeae of urethra, vagina/cervix and/or anal canal
- •Infection with Neisseria gonorrhoeae diagnosed by Gram-stained smear, APTIMA Combo 2 (NAAT) and/or direct cultivation
- •Willing to receive the routine treatment for Ng
排除标准
- •Use of antibiotics one week prior to gonorrhoea treatment
- •Current pregnancy in females
- •Only urethral infection in females
- •Ng infections diagnosed by Gram-stained smear, but subsequently not confirmed by NAAT or cultivation.
研究者
相似试验
尚未招募
3 期
Combination therapy in recurrence of enuresisIRCT20210714051893N1Qazvin University of Medical Sciences124
已完成
不适用
Clinical and radiographic results of treatment of periodontal intrabony defects with porous titanium granules and xenograft with collagen membranemoderate to severe chronic periodontitis.B99IRCT2015111425042N1vice chancellor for Research of Dental School ,Shahid Beheshti University of Medical Science15
已完成
不适用
Clinical Benefits of Following Therapy after Anti-HER2 Standard Therapy for HER2-positive, Unresectable and/or Metastatic Breast Cancer: a Retrospective Registry Study (KBCSG-TR 1917)HER2-positive, unresectable and/or metastatic breast cancerJPRN-UMIN000038296Kinki Breast Cancer Study Group128
尚未招募
不适用
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in a prior clinical study.Renal transplant rejectionAllograft rejection1002766510029149NL-OMON56013Sangamo Therapeutics France SAS8
进行中（未招募）
1 期
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR- Treg therapy, TX200-TR101) in a prior clinical study.Prevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 positive living donor.MedDRA version: 21.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2022-002440-40-DESangamo Therapeutics France SAS15